181 related articles for article (PubMed ID: 36242718)
1. The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension Study.
Frank S; Testa C; Edmondson MC; Goldstein J; Kayson E; Leavitt BR; Oakes D; O'Neill C; Vaughan C; Whaley J; Gross N; Gordon MF; Savola JM;
CNS Drugs; 2022 Nov; 36(11):1207-1216. PubMed ID: 36242718
[TBL] [Abstract][Full Text] [Related]
2. Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial.
; Frank S; Testa CM; Stamler D; Kayson E; Davis C; Edmondson MC; Kinel S; Leavitt B; Oakes D; O'Neill C; Vaughan C; Goldstein J; Herzog M; Snively V; Whaley J; Wong C; Suter G; Jankovic J; Jimenez-Shahed J; Hunter C; Claassen DO; Roman OC; Sung V; Smith J; Janicki S; Clouse R; Saint-Hilaire M; Hohler A; Turpin D; James RC; Rodriguez R; Rizer K; Anderson KE; Heller H; Carlson A; Criswell S; Racette BA; Revilla FJ; Nucifora F; Margolis RL; Ong M; Mendis T; Mendis N; Singer C; Quesada M; Paulsen JS; Brashers-Krug T; Miller A; Kerr J; Dubinsky RM; Gray C; Factor SA; Sperin E; Molho E; Eglow M; Evans S; Kumar R; Reeves C; Samii A; Chouinard S; Beland M; Scott BL; Hickey PT; Esmail S; Fung WL; Gibbons C; Qi L; Colcher A; Hackmyer C; McGarry A; Klos K; Gudesblatt M; Fafard L; Graffitti L; Schneider DP; Dhall R; Wojcieszek JM; LaFaver K; Duker A; Neefus E; Wilson-Perez H; Shprecher D; Wall P; Blindauer KA; Wheeler L; Boyd JT; Houston E; Farbman ES; Agarwal P; Eberly SW; Watts A; Tariot PN; Feigin A; Evans S; Beck C; Orme C; Edicola J; Christopher E
JAMA; 2016 Jul; 316(1):40-50. PubMed ID: 27380342
[TBL] [Abstract][Full Text] [Related]
3. Safety of Converting From Tetrabenazine to Deutetrabenazine for the Treatment of Chorea.
Frank S; Stamler D; Kayson E; Claassen DO; Colcher A; Davis C; Duker A; Eberly S; Elmer L; Furr-Stimming E; Gudesblatt M; Hunter C; Jankovic J; Kostyk SK; Kumar R; Loy C; Mallonee W; Oakes D; Scott BL; Sung V; Goldstein J; Vaughan C; Testa CM;
JAMA Neurol; 2017 Aug; 74(8):977-982. PubMed ID: 28692723
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial.
Furr Stimming E; Claassen DO; Kayson E; Goldstein J; Mehanna R; Zhang H; Liang GS; Haubenberger D;
Lancet Neurol; 2023 Jun; 22(6):494-504. PubMed ID: 37210099
[TBL] [Abstract][Full Text] [Related]
5. Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease.
Frank S; Anderson KE; Fernandez HH; Hauser RA; Claassen DO; Stamler D; Factor SA; Jimenez-Shahed J; Barkay H; Wilhelm A; Alexander JK; Chaijale N; Barash S; Savola JM; Gordon MF; Chen M
Neurol Ther; 2024 Jun; 13(3):655-675. PubMed ID: 38557959
[TBL] [Abstract][Full Text] [Related]
6. Deutetrabenazine: A Review in Chorea Associated with Huntington's Disease.
Heo YA; Scott LJ
Drugs; 2017 Nov; 77(17):1857-1864. PubMed ID: 29080203
[TBL] [Abstract][Full Text] [Related]
7. Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators.
Frank S
BMC Neurol; 2009 Dec; 9():62. PubMed ID: 20021666
[TBL] [Abstract][Full Text] [Related]
8. Real-World Experience With Deutetrabenazine for Huntington Disease Chorea.
Curtis K; Sung V
J Clin Pharmacol; 2024 Feb; 64(2):178-181. PubMed ID: 37565322
[TBL] [Abstract][Full Text] [Related]
9. Review of deutetrabenazine: a novel treatment for chorea associated with Huntington's disease.
Dean M; Sung VW
Drug Des Devel Ther; 2018; 12():313-319. PubMed ID: 29497277
[TBL] [Abstract][Full Text] [Related]
10. Indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease.
Claassen DO; Carroll B; De Boer LM; Wu E; Ayyagari R; Gandhi S; Stamler D
J Clin Mov Disord; 2017; 4():3. PubMed ID: 28265459
[TBL] [Abstract][Full Text] [Related]
11. Tetrabenazine: for chorea associated with Huntington's disease.
Scott LJ
CNS Drugs; 2011 Dec; 25(12):1073-85. PubMed ID: 22133328
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia.
Fernandez HH; Stamler D; Davis MD; Factor SA; Hauser RA; Jimenez-Shahed J; Ondo WG; Jarskog LF; Woods SW; Bega D; LeDoux MS; Shprecher DR; Anderson KE
J Neurol Neurosurg Psychiatry; 2019 Dec; 90(12):1317-1323. PubMed ID: 31296586
[TBL] [Abstract][Full Text] [Related]
13. The long-term effect of tetrabenazine in the management of Huntington disease.
Fasano A; Cadeddu F; Guidubaldi A; Piano C; Soleti F; Zinzi P; Bentivoglio AR
Clin Neuropharmacol; 2008; 31(6):313-8. PubMed ID: 19050408
[TBL] [Abstract][Full Text] [Related]
14. Deutetrabenazine for tardive dyskinesia and chorea associated with Huntington's disease: a review of clinical trial data.
Claassen DO; Philbin M; Carroll B
Expert Opin Pharmacother; 2019 Dec; 20(18):2209-2221. PubMed ID: 31613641
[No Abstract] [Full Text] [Related]
15. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial.
Huntington Study Group
Neurology; 2006 Feb; 66(3):366-72. PubMed ID: 16476934
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Fixed-Dose Deutetrabenazine in Children and Adolescents for Tics Associated With Tourette Syndrome: A Randomized Clinical Trial.
Coffey B; Jankovic J; Claassen DO; Jimenez-Shahed J; Gertz BJ; Garofalo EA; Stamler DA; Wieman M; Savola JM; Gordon MF; Alexander JK; Barkay H; Harary E
JAMA Netw Open; 2021 Oct; 4(10):e2129397. PubMed ID: 34661664
[TBL] [Abstract][Full Text] [Related]
17. A proof-of-concept study with SOM3355 (bevantolol hydrochloride) for reducing chorea in Huntington's disease.
Gamez J; Calopa M; Muñoz E; Ferré A; Huertas O; McAllister K; Reig N; Scart-Grès C; Insa R; Kulisevsky J
Br J Clin Pharmacol; 2023 May; 89(5):1656-1664. PubMed ID: 36494329
[TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy of Flexible-Dose Deutetrabenazine in Children and Adolescents With Tourette Syndrome: A Randomized Clinical Trial.
Jankovic J; Coffey B; Claassen DO; Jimenez-Shahed J; Gertz BJ; Garofalo EA; Stamler DA; Wieman M; Savola JM; Gordon MF; Alexander J; Barkay H; Harary E
JAMA Netw Open; 2021 Oct; 4(10):e2128204. PubMed ID: 34609495
[TBL] [Abstract][Full Text] [Related]
19. Deutetrabenazine for the treatment of Huntington's chorea.
Bashir H; Jankovic J
Expert Rev Neurother; 2018 Aug; 18(8):625-631. PubMed ID: 29996061
[TBL] [Abstract][Full Text] [Related]
20. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial.
Anderson KE; Stamler D; Davis MD; Factor SA; Hauser RA; Isojärvi J; Jarskog LF; Jimenez-Shahed J; Kumar R; McEvoy JP; Ochudlo S; Ondo WG; Fernandez HH
Lancet Psychiatry; 2017 Aug; 4(8):595-604. PubMed ID: 28668671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
